Artemis Investment Management LLP Boosts Stake in Repligen Co. (NASDAQ:RGEN)

Artemis Investment Management LLP grew its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 18.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 153,832 shares of the biotechnology company's stock after acquiring an additional 23,905 shares during the period. Artemis Investment Management LLP owned 0.27% of Repligen worth $22,143,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of RGEN. First Turn Management LLC acquired a new position in shares of Repligen during the third quarter worth $13,202,000. Thrivent Financial for Lutherans grew its position in shares of Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock valued at $95,037,000 after buying an additional 36,773 shares during the last quarter. Geneva Capital Management LLC increased its stake in shares of Repligen by 8.5% in the third quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company's stock valued at $20,638,000 after buying an additional 10,908 shares during the period. Integral Health Asset Management LLC raised its position in shares of Repligen by 20.0% during the second quarter. Integral Health Asset Management LLC now owns 60,000 shares of the biotechnology company's stock worth $7,564,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Repligen in the second quarter worth approximately $5,320,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on RGEN shares. Canaccord Genuity Group assumed coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price on the stock. Canaccord Genuity Group began coverage on Repligen in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective on the stock. Wolfe Research assumed coverage on Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating for the company. Royal Bank of Canada reissued an "outperform" rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Finally, StockNews.com raised shares of Repligen from a "sell" rating to a "hold" rating in a research report on Friday, January 3rd. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $185.20.

Repligen Trading Down 1.4 %

Repligen stock traded down $2.34 during mid-day trading on Monday, reaching $160.51. 753,582 shares of the company traded hands, compared to its average volume of 406,961. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The firm has a market capitalization of $8.99 billion, a price-to-earnings ratio of -433.80, a P/E/G ratio of 4.14 and a beta of 0.97. The firm's 50 day moving average price is $148.36 and its 200 day moving average price is $144.81.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company had revenue of $154.87 million for the quarter, compared to analysts' expectations of $153.34 million. During the same period in the prior year, the firm earned $0.23 earnings per share. The firm's revenue for the quarter was up 9.7% on a year-over-year basis. On average, analysts anticipate that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.